secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2026-11-10T21:45:24+00:00
Accession:  0001193125-26-455640
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 3.03, 1.01, 2.01, 5.02, 9.01, 2.02, 3.02, 5.03, 5.01, 5.05, 5.06
LLM model:  deepseek-v4.1-flash:cloud@v2

InMed closes merger with Mentari; renamed Mentari Therapeutics (MTRI), Mentari holders own ~99%
--------------------------------------------------------------------------------

- Closed Nov 6, 2026 merger: InMed became Mentari Therapeutics, ticker MTRI on Nasdaq, after 1-for-10 reverse split and redomestication from British Columbia to Nevada.
- Exchange ratio was 0.20065 Company shares per Mentari common/Series A share; Mentari Series Seed preferred converted at 0.00020065 Company Series A preferred per share.
- Post-close fully diluted: legacy InMed holders ~1.0%, Mentari holders ~99.0%, after $490.0M PIPE of 215,042,178 shares and 7,317,328 pre-funded warrants.
- PIPE included $52.7M of principal/accrued interest on Mentari convertible notes; $290M tranche priced off $125M valuation, additional $200M at 152.8% of that price.
- CVRs: one per InMed share held Nov 5, 2026, paying 100% of net proceeds from legacy InMed business sale in first year and 90% in second; 2-year term, extendable to 15 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000119312526455640/0001193125-26-455640-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000119312526455640/d539218d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-455640

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer